SAN DIEGO, May 25, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer, announced today that results from the Phase I clinical trial of MabVax's therapeutic antibody MVT-5873, being evaluated in advanced pancreatic cancer and other CA19-9 positive cancers, will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, IL, June 2 - 6, 2017.
As part of the presentation, MabVax will discuss the results of the Company's dose-escalation and safety trial, conducted over the last year in 32 patients with advanced pancreatic and colon cancer. Additionally, single agent MVT-5873 safety profile, efficacy, and reductions in serum CA19-9 levels over time will be presented.
Title of Presentation: Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, in patients with pancreatic cancer and other CA19-9 positive malignancies.
Abstract Number: 4110
Location: Gastrointestinal (Non-colorectal) Cancer Session
Session Date: Saturday, June 3rd
Time: 8:00 AM to 11:30 AM (CDT)
The Phase I therapeutic trial is an open-label, dose-escalation study evaluating the safety, tolerability and pharmacokinetics of MVT-5873. The first group of patients enrolled assess safety and determined the recommended Phase II dose of the antibody. The second patient group will establish the safety and dose of the antibody when administered with a standard-of-care chemotherapy. Dr. Eileen O'Reilly, associate Director of the David M. Rubenstein Center for Pancreatic Cancer Research, attending physician, member at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College is the lead investigator in the MVT-5873 Phase I clinical trial.
About MabVax Therapeutics Holdings, Inc.
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. Our lead antibody is directed at an antigen target expressed on more than 90% of pancreatic cancers and a significant amount of other GI and lung cancers, making the antibody potentially broadly applicable to a wide variety of patients suffering from difficult to treat cancers. With our collaborators including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon, Honor Health and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase I clinical studies, and demonstrated early safety, specificity for the target and an early efficacy signal. Results of these trials should be published by mid-year 2017. Additionally, our Phase I clinical study of our radioimmunotherapy product designated as MVT-1075 has been authorized to proceed by the FDA and will soon commence with patient enrollment. For additional information, please visit the Company's website, www.mabvax.com.
Forward Looking Statements:
This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to presentations at the ASCO Annual Meeting. We have no assurance that all the product development pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended and supplemented from time to time and the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mabvax-therapeutics-to-present-phase-i-clinical-trial-results-of-mvt-5873-for-the-treatment-of-advanced-pancreatic-cancer-in-poster-presentation-at-the-2017-asco-annual-meeting-300462602.html
SOURCE MabVax Therapeutics Holdings, Inc.
Released May 25, 2017